[Leslie Carol Botha: Finally – people are waking up to the fact that the HPV vaccine is a scandal. Why would anyone choose this vaccine when carcinogenicity has not been tested? When the virus itself passes through most (90%) women’s bodies in less than 2 years. And when cervical cancer is not even in the top 10 cancers in the U.S. The vaccine is potentially doing more harm than good. Our colleagues in India have done an outstanding job in making the government in their country aware of the unethical and immoral vaccine campaign against innocent, under-informed children and their parents.]
Indian HPV vaccine trial should never have happened
Nature News Blog | Posted by Brian Owens
Posted on behalf of Priya Shetty.
A human-papillomavirus (HPV) vaccine trial in India shut down in 2010 by the Indian government amid accusations of unethical behaviour has been further slammed by scientists who argue that it should never have been started at all.
A study published today in the Journal of the Royal Society of Medicine by Allyson Pollock, a public-health researcher at Queen Mary, University of London, and her colleagues, says that there is not enough evidence that cervical cancer affects enough women in India to warrant a vaccine.
The need for an HPV vaccine has been overhyped globally by non-governmental organizations (NGOs) pushing for its use, Pollock told Nature, especially given “the absence of strong epidemiological evidence and robust comprehensive cancer-surveillance systems in many countries”, including India.
In India, say Pollock’s team, cancer surveillance, registration and monitoring are so poor that it would be impossible to tell whether the vaccine reduced cervical-cancer rates. In addition, they say, incidence rates for cervical cancer are low compared to the rest of the world, and have fallen from around 43 cases per 100,000 in 1982–83 to around 22 per 100,000 in 2004–05.
The trial of more than 23,000 girls from Gujarat and Andhra Pradesh states was run by the international health NGO PATH. However, in a statement released shortly after the trial was halted, the NGO pointed out that the trial HPV vaccines used (Gardasil and Cervarix) were already licensed for sale in India, as well as in more than 100 other countries.
Even though PATH received appropriate ethics approval by the Indian government, Pollock feels “there should have been much more scrutiny of the decision to allow PATH to proceed with the vaccine trial in the first place,” she added.